# Philippe Gabríel Steg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/philippe-gabriel-steg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 188,298 |
| Field | Acute Myocardial Infarction Research |
| h-index | 176 |
| i10-index | 941 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5003831287 |
| ORCID iD | 0000-0001-6896-2941 |
| Works | 1,917 |

## Researcher papers

Showing 12 of 44.

- [2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation](https://scholariq.org/papers/2017-esc-guidelines-for-the-management-of-acute-myocardial-infarction-in/)
- [Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes](https://scholariq.org/papers/ticagrelor-versus-clopidogrel-in-patients-with-acute-coronary-syndromes/)
- [ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation](https://scholariq.org/papers/esc-guidelines-for-the-management-of-acute-myocardial-infarction-in-patients/)
- [Clinical End Points in Coronary Stent Trials](https://scholariq.org/papers/clinical-end-points-in-coronary-stent-trials/)
- [Standardized Bleeding Definitions for Cardiovascular Clinical Trials](https://scholariq.org/papers/standardized-bleeding-definitions-for-cardiovascular-clinical-trials/)
- [Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome](https://scholariq.org/papers/alirocumab-and-cardiovascular-outcomes-after-acute-coronary-syndrome/)
- [Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus](https://scholariq.org/papers/saxagliptin-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure](https://scholariq.org/papers/rapid-measurement-of-b-type-natriuretic-peptide-in-the-emergency-diagnosis-of/)
- [Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia](https://scholariq.org/papers/cardiovascular-risk-reduction-with-icosapent-ethyl-for-hypertriglyceridemia/)
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS](https://scholariq.org/papers/2017-esc-focused-update-on-dual-antiplatelet-therapy-in-coronary-artery-disease/)
- [COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up](https://scholariq.org/papers/covid-19-and-thrombotic-or-thromboembolic-disease-implications-for-prevention/)
- [Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events](https://scholariq.org/papers/clopidogrel-and-aspirin-versus-aspirin-alone-for-the-prevention-of/)

## Researcher topics

- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.